| Name | 2-[1-[2-[(3R,5S)-1-(3-acetyloxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid |
|---|---|
| Synonyms |
4-Piperidineacetic acid, 1-[2-[(3R,5S)-1-[3-(acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazin-3-yl]acetyl]
1-[[(3R,5S)-1-[3-(Acetyloxy)-2,2-dimethylpropyl]-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-2-oxo-4,1-benzoxazin-3-yl]acetyl]-4-piperidineacetic acid 2-[1-[2-[1-(3-Acetoxy-2,2-diMethylpropyl)-7-chloro-5(S)-(2,3-diMethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazin-3(R)-yl]acetyl]piperidin-4-yl]acetic acid 2-(1-(2-((3R,5S)-1-(3-Acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydrobenzo[e][1,4]oxazin-3-yl)acetyl)piperidin-4-yl)acetic acid Lapaquistat acetate LAPAQUISTAT UNII-IUH3AY74O3 Lapaquistat and Lapaquistat Acetate Lapaquistat Acetate (TAK-475) TAK-475 |
| Description | Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene[1]. Lapaquistat acetate (TAK-475) is originally intended use to Mevalonate Kinase Deficiency (MKD), it is effective at lowering low-density lipoprotein cholesterol, but it might cause liver damage[2]. |
|---|---|
| Related Catalog | |
| Target |
Squalene synthase[1] |
| References |
| Molecular Formula | C33H41ClN2O9 |
|---|---|
| Molecular Weight | 645.14000 |
| Exact Mass | 644.25000 |
| PSA | 131.91000 |
| LogP | 4.87400 |